Kip A. West

Celldex Therapeutics (United States) — United States

Medicine · Health Sciences

27h-index6.8kcitations66works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(14), Protease and Inhibitor Mechanisms(10), PI3K/AKT/mTOR signaling in cancer(10), Heat shock proteins research(9), Cancer Research and Treatments(6)

Publications66 total

Abstract B105: Oral small molecule MYC condensate modulators (c-mods) induce robust anti-tumor responses in preclinical solid tumor models
Molecular Cancer Therapeutics·2025
Abstract 6987: MYC condensate-modulating small molecules demonstrate robust antitumor activity in animal models of ovarian cancer and other solid tumors
Cancer Research·2025
Abstract 1751: Beta catenin c-mods are orally bioavailable small-molecules targeting Wnt-driven tumors
Cancer Research·2025· 1 cited
Abstract LB199: Condensate modulator sequesters beta-catenin into depot condensates and demonstrates competitive anti-tumor activity in animal models ofcolorectal cancer
Cancer Research·2024
BOS-371, a monoclonal antibody against IL1RAP: Characterization in preclinical models of AML.
Journal of Clinical Oncology·2023· 3 cited
Supplementary Figure 3 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
2023Open Access
Data from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
2023Open Access
Supplementary Figure 1 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
2023Open Access
Supplementary Figure 3 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
2023Open Access
Supplementary Figure 2 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
2023Open Access
Data from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
2023Open Access
Supplementary Figure Legends 1-3 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
2023Open Access
Supplementary Figure 1 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
2023Open Access
Supplementary Figure 2 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
2023Open Access
Supplementary Figure Legends 1-3 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
2023Open Access
Metabolic modulation of tumours with engineered bacteria for immunotherapy
Nature·2021· 543 cited
Metabolic modulation of tumors with engineered bacteria for immunotherapy
Research Square (Research Square)·2021· 1 citedOpen Access
577 Engineered non-pathogenic synthetic biotic producing L-arginine synergize with PD-1-based cancer immunotherapy
Regular and Young Investigator Award Abstracts·2020Open Access
Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity
Nature Communications·2020· 411 citedOpen Access
An engineered <i>E. coli</i> Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans
Science Translational Medicine·2019· 368 cited
page 1 of 4Next →

Frequent Co-authors

Emmanuel Normant(12), Phillip A. Dennis(10), Kelly L. Slocum(10), Alice R. Lim(8), Christian Fritz(7), Vito J. Palombella(6), Maurizio Scaltriti(6), Violeta Serra(6), Marta Guzmán(6), Varenka Rodriguez(6), Ludmila Prudkin(6), José Jiménez(6), Claudia Aura(6), Ning Li(5), Paul Miller(5), Anna Sokolovska(5), John Brognard(5), Ilona Linnoila(5), Curtis C. Harris(5), Steven A. Belinsky(5)